Archives
-
Vernakalant Hydrochloride: Rapid AF Conversion
2026-09-16
Vernakalant Hydrochloride, also known as RSD1235, is an atrial-selective antiarrhythmic agent studied for rapid conversion of atrial fibrillation. Its value comes from combined atrial ion-channel modulation, rapid intravenous exposure, and selective prolongation of atrial refractoriness.
-
NIH/3T3 Cells: Recovery, Culture, and QC
2026-09-15
This guide provides a practical recovery, expansion, transfection, viral proliferation, and oncogene research workflow for NIH/3T3 Cells supplied as a cryopreserved mouse fibroblast line. It is intended for controlled laboratory research, not for clinical, diagnostic, or quantitative performance claims beyond the product dossier.
-
SAR131675: Selective VEGFR-3 Inhibitor Guide
2026-09-15
SAR131675 is a selective ATP-competitive VEGFR-3 inhibitor with nanomolar biochemical and cellular activity. It is a useful anti-lymphangiogenic and anti-angiogenic research compound, but its discontinued development and poor solvent compatibility limit translational use.
-
3X (DYKDDDDK) Peptide: Workflow Guide
2026-09-14
Use the 3X (DYKDDDDK) Peptide as a practical competition reagent, detection control, and purification aid for FLAG-tagged constructs. This guide connects routine affinity workflows with membrane-protein structural studies, including the VPS13A–XKR1 mechanism described in a recent cryo-EM study.
-
Engineered mRNA Rescues Niemann-Pick C1 Cells
2026-09-14
Furtado and colleagues used codon optimization and N1-methylpseudouridine modification to improve NPC1 mRNA expression and restore cholesterol handling in fibroblasts from a patient with Niemann-Pick disease type C1. The study links optimized mRNA design to functional rescue, while also highlighting the importance of secondary structure and disease-relevant validation assays.
-
EdU Flow Cytometry Assay Kits (Cy5): Practical Guide
2026-09-13
EdU Flow Cytometry Assay Kits (Cy5) provide a workflow for measuring DNA synthesis during S-phase by combining EdU incorporation with copper-catalyzed azide-alkyne cycloaddition (CuAAC) and Cy5 fluorescence. The assay is suitable for flow cytometry-based proliferation studies, but it should not be used alone to infer viability, completed cell division, cell-cycle duration, or genotoxicity.
-
FGFR3 Inhibition in SLC26A2 Chondrodysplasia
2026-09-12
The reference study combines genetic mouse models, inducible postnatal deletion, chondrocyte assays, and pharmacological intervention to show that excessive FGFR3 signaling contributes to SLC26A2-related chondrodysplasia. Its findings support NVP-BGJ398 as a preclinical tool for testing FGFR3 pathway inhibition, while also highlighting the limits of translating a pan-FGFR inhibitor from mice to human skeletal disease.
-
Deferasirox in Ferroptosis and Iron-Metabolism Assays
2026-09-11
Deferasirox is an oral iron chelator that gives researchers a practical way to perturb labile iron, redox balance, and ferroptosis sensitivity in cellular models. This workflow-focused guide connects iron-overload biology with hepatocellular carcinoma research while separating validated findings from testable experimental hypotheses.
-
Sex Differences in Angiotensin II Hypertension
2026-09-11
Xue, Pamidimukkala, and Hay used radiotelemetry in conscious, freely moving mice to show that chronic angiotensin II produces a substantially greater hypertensive response in males than in females. Gonadectomy, baroreflex testing, and ganglionic blockade further linked this divergence to sex-dependent hormonal and autonomic regulation rather than to baseline blood pressure differences alone.
-
WNT5a/GSK3/β-Catenin Controls FAP Adipogenesis
2026-09-10
The reference study identifies the WNT5a/GSK3/β-catenin axis as a central regulator of adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors (FAPs). By combining pharmacological perturbation, single-cell mass cytometry, transcriptomic integration, and mouse models, it links β-catenin stabilization to reduced PPARγ-driven adipogenesis and improved satellite-cell support.
-
PS Nanoplastics, NMNAT3, and Placental Ferroptosis
2026-09-10
This study identifies an NMNAT3-dependent metabolic cascade linking gestational polystyrene nanoplastic exposure to placental NAD+ depletion, mitochondrial dysfunction, ferritinophagy, ferroptosis, and fetal growth restriction. Its integrated metabolomics, cellular rescue, and nicotinamide-intervention strategy provides a mechanistic framework for investigating nanoplastic-induced reproductive toxicity and potential metabolic countermeasures.
-
Light-Inducible RNA Release for Regulated Gene Therapy
2026-09-09
A 2026 Trends in Biotechnology study presents a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translation stage. By combining LIRP with AAV delivery and light-accessible tissues, the authors demonstrate reversible regulation in models of obesity and retinal neovascular disease, offering a safety-oriented framework for on-demand gene therapy.
-
Renal OCT2/MATE1 Inhibition by 5-HT3 Antagonists
2026-09-09
George and colleagues compared five 5-HT3 antagonist drugs in complementary cellular models of renal organic cation transport. Their results identify transporter-specific inhibition patterns and show that several agents, including tropisetron, can reduce OCT2/MATE1-dependent secretion in vitro, supporting further investigation of cationic drug interactions.
-
Cycloastragenol in Glucocorticoid-Induced Osteonecrosis
2026-09-08
A 2024 in vivo study shows that cycloastragenol reduced femoral-head necrosis and trabecular bone loss in a methylprednisolone-induced rat model of glucocorticoid-induced osteonecrosis of the femoral head. By combining micro-CT, angiography, histology, qPCR, and Western blotting, the study links structural preservation to reduced osteoclast activity and altered RANKL–OPG signaling, while leaving important translational questions unresolved.
-
Serine/Glycine-Free Diet and PD-L1 Lactylation
2026-09-08
The Cell Metabolism study by Tong et al. shows that a serine/glycine-free diet can inhibit colorectal cancer growth and increase cytotoxic T-cell activity, while simultaneously promoting immune evasion through PD-L1 lactylation. Its preclinical and early clinical findings support combining metabolic dietary intervention with immune checkpoint blockade, but randomized efficacy studies and more detailed clinical validation remain necessary.